Epacadostat, Cladribine and Cytarabine (ECC) in AML
Status:
Withdrawn
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting
toxicities (DLTs) of epacadostat when added to the cladribine/cytarabine chemotherapy in
relapsed / refractory AML patients fit for intensive treatment